COVID-19: diretriz conjunta do ECDC e EMA sobre a 4ª dose de vacinas de mRNA.

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Conteúdos relacionados:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Comentário no Twitter (fio – clique para saber mais)

#JustPublished!#ECDC and @EMA_News issue advice on fourth doses of mRNA #COVID19 vaccines.

Read the full joint statement: https://t.co/hBuOlrfKOD pic.twitter.com/aO5vSyYvTk

— ECDC (@ECDC_EU) April 6, 2022